Quadruple Therapies Including Immunotherapy Agents Show Benefit in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological cancer, and it originates from malignant plasma cells within the bone marrow, leading to overproduction of abnormal cells that cause suppressed immune function, brittle bones, and organ …